William Blair downgraded RayzeBio (RYZB) to Market Perform from Outperform after the company agreed to be acquired by Bristol Myers Squibb (BMY) for $62.50 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RYZB:
- M & A News: Bristol-Myers (NYSE:BMY) Snaps Up RayzeBio (NASDAQ:RYZB) for $4.1B
- Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
- RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Eight new option listings and one option delisting on November 8th
- RayzeBio to Participate in Upcoming Investor Conferences in November 2023